Sunitinib in refractory adrenocortical carcinoma: A phase II, single-arm, open-label trial

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages 3495-3503

  Kroiss, Matthias ^a   Quinkler, Marcus ^b   Johanssen, Sarah ^a   Van Erp, Nielka P ^c   Lankheet, Nienke ^d   Pöllinger, Alexander ^b   Laubner, Katharina ^a   Strasburger, Christian J ^b   Hahner, Stefanie ^a   Müller, Hans Helge ^e   Allolio, Bruno ^a   Fassnacht, Martin ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOCHROME P450 3A4; DOXORUBICIN; ETOPOSIDE; LIVER ENZYME; MITOTANE; N DEETHYLSUNITINIB; STREPTOZOCIN; SUNITINIB;

ABDOMINAL PAIN; ABSCESS; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CAUDA EQUINA SYNDROME; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; ENZYME ACTIVITY; ENZYME INDUCTION; ESOPHAGITIS; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GERMANY; HAND FOOT SYNDROME; HEART FAILURE; HEART INFARCTION; HEMORRHOID; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INFECTION; JAUNDICE; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAIL DISCOLORATION; NAIL DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT HEMORRHAGE; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SKIN BLEEDING; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT OBSTRUCTION;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MITOTANE; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867255648     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1419     Document Type: Article

References (40)

1. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A 2006 Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30:872-878 (Pubitemid 43724119)
2. Fassnacht M, Libé R, Kroiss M, Allolio B 2011 Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 7:323-335
3. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650-2655 (Pubitemid 44024632)
4. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25:891-897 (Pubitemid 32666390)
5. Veytsman I, Nieman L, Fojo T 2009 Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 27:4619-4629
6. Fassnacht M, Allolio B 2009 Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23:273-289
7. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M, Baudin E 2007 Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92:148-154 (Pubitemid 46067523)
8. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI 2010 The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 46:713-719
9. Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, Dumont F, Dechamps F, Caramella C, Chanson P, Lanoy E, Borget I, Schlumberger M 2011 Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer 2:363-371
10. Zini L, Porpiglia F, Fassnacht M 2011 Contemporary management of adrenocortical carcinoma. Eur Urol 60:1055-1065
11. Bergenstal D, Lipsett M, Moy R, Hertz R 1959 Regression of adrenal cancer and suppression of adrenal function in men by o,p-DDD. Trans Am Physicians 72:341
12. Hahner S, Fassnacht M 2005 Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6:386-394 (Pubitemid 40561415)
13. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E 2011 Plasma concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844-1851
14. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M 2001 Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385-1392 (Pubitemid 32947821)
15. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B 2012 Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189-2197
16. Samnotra V, Vassilopoulou-Sellin R, Fojo AT A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Proc Annual Meeting of the Society of Clinical Oncologists, Chicago, IL, 2007, p 15527 (Abstract)
17. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S 2006 The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 13:535-540 (Pubitemid 43886675)
18. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Ritte C, Strasburger C, Allolio B, Fassnacht M 2008 Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93:2057-2062 (Pubitemid 351831515)
19. Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B, Fassnacht M 2010 Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 162:349-356
20. Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S, Volante M, Daffara F, Generali D, Leboulleux S, Perotti P, Baudin E, Papotti M, Terzolo M 2012 Phase II study of weekly paclitaxel and sorafenib as second/third line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 166:451-458
21. Fassnacht M, Kreissl MC, Weismann D, Allolio B 2009 New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123:117-141
22. Chow LQ, Eckhardt SG 2007 Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896 (Pubitemid 350002890)
23. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
24. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338 (Pubitemid 44528723)
25. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
26. Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W 2008 Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 36:905-916
27. Lodish MB, Stratakis CA 2010 Endocrine side effects of broadacting kinase inhibitors. Endocr Relat Cancer 17:R233-R244
28. Kroiss M, Reuss M, Kohner D, Johanssen S, Beyer M, Zink M, Hartmann M, Dhir V, Wudy SA, Arlt W, Sbiera S, Allolio B, Fassnacht M 2011 Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. Front Endocrinol 2:27
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000Newguidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
30. Moolenaar AJ, Niewint JW, Oei IT 1977 Estimation of o,p′-DDD in plasma by gas-liquid chromatography. Clin Chim Acta 76:213-218 (Pubitemid 8067370)
31. Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Walraven M, Lind JS, Tibaldi C, Verheul HM, Peters GJ 2010 Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:1059-1068
32. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35 (Pubitemid 46630490)
33. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y 1994 Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444-1453 (Pubitemid 24181019)
34. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G 2009 Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15:668-676
35. Demeure MJ, Bussey KJ, Kirschner LS 2011 Targeted therapies for adrenocortical carcinoma: IGF and beyond. Horm Cancer 2:385-392
36. van Erp NP, Gelderblom H, Guchelaar HJ 2009 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706
37. van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J, Gelderblom H 2011 Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 164:621-626
38. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M 2011 Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 75:585-591
39. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA 2012 Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30:1371-1377
40. Clopper CJ, Pearson ES 1934 The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413